Oncimmune (ONC) Releases Quarterly Earnings Results

Oncimmune (LON:ONC) released its quarterly earnings data on Tuesday. The company reported GBX (5.70) (($0.08)) earnings per share for the quarter, Bloomberg Earnings reports. The firm had revenue of £800 million during the quarter. Oncimmune had a negative net margin of 2,521.78% and a negative return on equity of 81.75%.

Shares of Oncimmune (LON ONC) opened at GBX 145.50 ($2.01) on Thursday. The company has a market capitalization of $88.48 and a PE ratio of -1,455.00. Oncimmune has a twelve month low of GBX 100 ($1.38) and a twelve month high of GBX 150 ($2.07).

ONC has been the topic of several analyst reports. Berenberg Bank initiated coverage on Oncimmune in a report on Friday, January 19th. They set a “buy” rating and a GBX 169 ($2.33) target price on the stock. Bryan, Garnier & Co raised their target price on Oncimmune from GBX 154 ($2.13) to GBX 168 ($2.32) and gave the company a “buy” rating in a report on Tuesday.

ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2018/02/15/oncimmune-onc-releases-quarterly-earnings-results.html.

About Oncimmune

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply